Two truncating variants in FANCC and breast cancer risk
Thilo Dörk(Hannover Re (Germany)), Mia M. Gaudet(Cancer Prevention Institute of California), Marina Bermisheva(Russian Academy of Sciences), Federico Canzian(German Cancer Research Center), Volker Arndt(German Cancer Research Center), Lin Fritschi(Curtin University), Hiltrud Brauch(German Cancer Research Center), Natalia Bogdanova(Medizinische Hochschule Hannover), Fergus J. Couch(Mayo Clinic), Miriam Dwek(University of Cambridge), Peter A. Fasching(Universitätsklinikum Erlangen), Jenny Chang‐Claude(Universität Hamburg), Manuela Gago-Domínguez(University of Southern California), Susan M. Gapstur(Centre international de recherche sur le cancer), Jonine D. Figueroa, José Á. García-Sáenz(Hospital Clínico San Carlos), Mikael Eriksson(Herlev Hospital), Kamila Czene(Karolinska Institutet), Matthias W. Beckmann(Universitätsklinikum Erlangen), Arif B. Ekici(University Medical Center Groningen), Thomas U. Ahearn(Harvard University), Marike Gabrielson(Karolinska Institutet), Joe Dennis(University of Cambridge), Irene L. Andrulis(University of Toronto), Sabine Behrens(German Cancer Research Center), Christine L. Clarke(Memorial University of Newfoundland), Henrik Flyger(Gentofte Hospital), Chi Gao(North China University of Science and Technology Affiliated Hospital), Carl Blomqvist(University of Helsinki), Ji‐Yeob Choi(Seoul National University), Stig E. Bojesen(University of Copenhagen), Montserrat García‐Closas(Institute of Cancer Research), Hermann Brenner(Universidad de Granada), Hoda Anton‐Culver(University of California, Irvine), Laura E. Beane Freeman(National Cancer Institute), D. Gareth Evans(Manchester Academic Health Science Centre), Kristan J. Aronson(Queen's University), Stephen J. Chanock(National Cancer Institute), Qin Wang(University of Cambridge), Hans Christiansen(Medizinische Hochschule Hannover), Tsun Leung Chan(University of Hong Kong), Barbara Burwinkel(German Cancer Research Center), Alicia Beeghly‐Fadiel(University of Helsinki), Paolo Peterlongo(IFOM), Mary B. Daly(Fox Chase Cancer Center), Isabel dos‐Santos‐Silva(London School of Hygiene & Tropical Medicine), Manjeet K. Bolla(University of Cambridge), Annelie Augustinsson(Lund University)
Cited by 7
Related Papers
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k